Solus is a leading supplier of naturally derived powder ceramides, a high-growth global market with further potential to extend into formulated ceramides. The number of new personal care products containing ceramides has doubled over the last five years, principally for skin care but increasingly for hair care formulations. Access to Croda's formulation capabilities will accelerate development of Solus' formulated ceramides to create even greater value for our customers globally and address exciting, formulated ceramide demand.
Solus also brings a portfolio of phospholipids, spanning pharmaceutical applications and beauty care. These naturally derived phospholipids are produced at a GMP plant and can be used as delivery systems for pharmaceutical actives and cosmetics. This will strengthen our Pharma presence in
Solus' growth will be accelerated by Croda's ownership through access to our technical and innovation capabilities, particularly in formulation, and by accessing our global selling network. The acquisition will give Croda greater ability to serve luxury beauty customers in
Commenting,
"This is a strategic bullseye for Croda, consolidating our position as a global leader in supplying sustainable, natural actives for personal care across three critical technology platforms of peptides, ceramides and retinol. It significantly enhances our sustainable biotechnology capabilities and adds a
The acquisition is subject to regulatory approval.
Croda will report its financial results for 2022 on
About Solus Biotech
Solus Biotech has more than 30 years' experience in biotechnology and fermentation. The business generated approximately
Further information
For enquiries contact:
Investors:
Press:
.
(C) 2023 M2 COMMUNICATIONS, source